Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical study of Octagam 5% in primary immunodeficiency diseases
2012-000792-16Phase 3Completed
- Sponsor
- Octapharma
- Start
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Human normal immunoglobulin G in Immunogenetic disorder and X-linked agammaglobulinemia (XLA), sponsored by Octapharma. Primary endpoint: Pharmacokinetic profile of Octagam 5%. Started Mar 2012; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
Immunogenetic disorderX-linked agammaglobulinemia (XLA)
Beyond the preview
Go deeper on 2012-000792-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000792-16.